- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Luna Innovations Incorporated (LUNA 3.13, +0.03, +0.97%) a company focusing on sensing, instrumentation and nanotechnology, announced today it will report its fourth quarter and full year financial results for the period ended December 31, 2009, in a conference call with investors. Kent A. Murphy, Chief Executive Officer, and Dale Messick, Chief Financial Officer, will host the call on Thursday, March 4, 2010 at 5:00 p.m. (EST).
The investor conference call will be available via live webcast on the Luna Innovations website at www.lunainnovations.com under the tab "Investor Relations." To participate by telephone, the domestic dial-in number is 1.866.804.6923 and the international dial-in number is 1.857.350.1669. The participant access code is 79052173. Investors are advised to dial in at least five minutes prior to the call to register. The webcast will be archived on the company's website under "Webcasts and Presentations" for 30 days following the conference call.
About Luna Innovations
Luna Innovations Incorporated (www.lunainnovations.com) is focused on sensing and instrumentation, and pharmaceutical nanomedicines. Luna develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. The company's products are used to measure, monitor, protect and improve critical processes in the markets we serve. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia.
For more information, please click here
Luna Innovations Incorporated
Dale Messick, CFO, 1-540-769-8400
Copyright © Luna InnovationsIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015